Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01141504 · ClinicalTrials.gov registry record · Phase 1
Effect of Oral Adenosine-triphosphate (ATP) on Human Muscle Performance
A Phase 1 study of Healthy Subjects, sponsored by Metabolic Technologies.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT01141504: Completed Phase 1 study of Healthy Subjects, sponsored by Metabolic Technologies.
NCT01141504 is a Phase 1 study of Healthy Subjects that has completed, run by Metabolic Technologies. The registered enrollment target is 16 participants, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01141504, a Phase 1 study of Healthy Subjects, has completed, sponsored by Metabolic Technologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
Adenosine-triphosphate (ATP) serves as the sole energy source for muscle contraction. Therefore human performance of brief maximal exercise is limited, in part, by the availability of ATP to the contracting muscle. Because muscle ATP storage is small (enough to sustain maximal exercise for less than 1 second), factors that enhance either storage or resynthesis of ATP may have a positive impact on repeated muscle contractions. The current study will test the hypothesis that increasing ATP availability to muscle via oral supplementation will improve performance of repeated high intensity exercise as measured by a) work performed in each of the three 50 contraction fatigue tests, b) sum of total work performed, and c) percentage decrement in total work from the first to third third 50 contraction test.
Primary Outcome
The work and total work performed in 3 exercise fatigue tests given after 15 days of nutritional intervention.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT PeakATP 250
- DIETARY_SUPPLEMENT PeakATP 400
- DIETARY_SUPPLEMENT PeakATP 400 plus proprietary blend
Study Locations (1)
Iowa
- Iowa State University - Ames
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2010-06 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
What the finished NCT01141504 record still lists
NCT01141504 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Healthy Subjects appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT01141504 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT01141504 about?
NCT01141504 is a clinical study titled "Effect of Oral Adenosine-triphosphate (ATP) on Human Muscle Performance". Adenosine-triphosphate (ATP) serves as the sole energy source for muscle contraction. Therefore human performance of brief maximal exercise is limited, in part, by the availability of ATP to the contracting muscle. Because muscle ATP storage is small (enough to sustain maximal exercise for less than...
What is the current status of trial NCT01141504?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2010-06. Estimated completion is 2011-10.
What conditions does trial NCT01141504 study?
This clinical trial studies the following conditions: Healthy Subjects.
What interventions are being tested in trial NCT01141504?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), PeakATP 250 (DIETARY_SUPPLEMENT), PeakATP 400 (DIETARY_SUPPLEMENT), PeakATP 400 plus proprietary blend (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01141504?
This trial is sponsored by Metabolic Technologies, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01141504 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Subjects
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01141504's enrollment target sits among peer trials
16 59th of 69 higher than 10 of 69 other Healthy Subjects trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Subjects trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I Study of ICP-332 in Healthy Subjects
RECRUITING · Phase 1
-
A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects
RECRUITING · Phase 1
-
Phase 1 Study of Intravaginal KB15A
RECRUITING · Phase 1
-
A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations
COMPLETED · Phase 1
-
Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol®
COMPLETED · Phase 1
-
A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia